Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q2 2016 · 10-Q
Revenue$33.34M$33.34M±0.0% vs Q2 2015 Net Income-$26.88M-$26.88MN/M vs Q2 2015 EPS Diluted$0.02$0.02±0.0% vs Q2 2015 Gross Profit$5,391,000±0.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Operating Cash Flowderived-$12,845,000N/M Free Cash Flowderived-$14,012,000N/M Margins · derivedGross margin16.2%±0.0 pt vs Q2 2015
Operating margin-65.2%−77.9 pt vs Q2 2015
Net margin-80.6%±0.0 pt vs Q2 2015
ended Jun 30, 2016 · filed Aug 9, 2016 · 40 d after period end